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Abstract
Background: Dysregulated expression and splicing of cell adhesion marker CD44 is found in many
types of cancer. In prostate cancer (PC) specifically, the standard isoform (CD44s) has been found
to be downregulated compared with benign tissue whereas predominant variant isoform CD44v7-
10 is upregulated. Mitogen-activated protein kinase pathways and paracrine calcitonin are two
common factors linked to dysregulated expression and splicing of CD44 in cancer. Calcitonin has
been found to increase proliferation and invasion in PC acting through the protein kinase A
pathway.
Methods: In androgen-independent PC with known high CD44v7-10 expression, CD44 total and
CD44v7-10 RNA or protein were assessed in response to exogenous and endogenous calcitonin
and to inhibitors of protein kinase A, MEK, JNK, or p38 kinase. Benign cells and calcitonin receptor-
negative PC cells were also tested.
Results: MEK or p38 but not JNK reduced CD44 total RNA by 40%–65% in cancer and benign
cells. Inhibition of protein kinase A reduced CD44 total and v7-10 protein expression. In calcitonin
receptor-positive cells only, calcitonin increased CD44 variant RNA and protein by 3 h and
persisting to 48 h, apparently dependent on an uninhibited p38 pathway. Cells with constitutive CT
expression showed an increase in CD44v7-10 mRNA but a decrease in CD44 total RNA.
Conclusion: The MEK pathway increases CD44 RNA, while calcitonin, acting through the protein
kinase A and p38 pathway, facilitates variant splicing. These findings could be used in the
formulation of therapeutic methods for PC targeting CD44 alternate splicing.
Background
CD44, a transmembrane glycoprotein, is the product of a
gene that can undergo extensive alternate splicing. The
standard (CD44s) isoform is ubiquitous but tissue-spe-
cific isoforms may include an assortment of 10 variant (v)
exons (CD44v). CD44 facilitates multiple cellular func-
tions. CD44 enables cell-cell and cell-matrix adhesion –
primarily to its main ligand hyaluronan, and links the cell
membrane to the actin cytoskeleton, modulating motility.
CD44 is universally dysregulated in human cancer, and
this imbalance of isoforms allows tumor growth and inva-
sion [1-8]. CD44v are expressed in prostatic secrectory
cells while CD44s is found in the whole epithelium.
About 30% of cases of prostate cancer (PC) undergo a
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other adhesion molecules permit this transition in which
tumor cells detach, interact with proteins that digest stro-
mal matrix, migrate through matrix, and intravasate into
lymphovascular channels.
By isolating RNA from clinical PC specimens, we discov-
ered that the major variant isoform expressed in PC is
CD44v7-10. This PC signature was consistently present in
both primary and metastatic PC [1-3]. Interference against
this CD44v caused a 69% reduction in invasion index
compared to untreated control cells[3]. Moreover, PC
loses the splicing ability to produce the CD44s expressed
in benign prostate[3,9,10]. CD44 must oligomerize to
bind matrix ligands or to cause metastasis[11] and variant
isoforms, with longer extracellular tails, have altered abil-
ity to complex[12]. We found that the CD44v7-10 iso-
form makes PC cells preferentially bind to fibronectin
rather than hyaluronan; re-expression of CD44s causes
the predominant ligand to revert from fibronectin back to
hyaluronan[4]. In mouse xenografts of PC-3 prostate
tumor, forced expression of CD44s reduced growth in vitro
and tumorigenicity[5], and our use of RNAi against
CD44v7-10 in xenografts yielded similar effects (unpub-
lished results).
In PC, calcitonin (CT) acts as a paracrine growth factor
that up-regulates CD44 variant[4,6]. In histologic speci-
mens PC, but not benign secretory epithelium, contains
CT[13] and its receptor (CTR)[14], and CT exerts para-
crine effects that promote proliferation[15], invasion[16],
and metastasis[17]. CTR, essential for prostate cancer
tumorigenicity[18], is coupled to the transduction protein
Gsα. We have shown that CT promotes alternate splicing
leading to CD44v7-10 mRNA and protein[4,6] by acting
through Gsα signaling[3]. Gsα stimulates the cyclic AMP
signaling cascade[17,19] and protein kinase A (PKA)[16].
PKA, in turn, acts on the 3 main MAPK pathways: a growth
factor-responsive pathway that uses MAP2K (also called
MEK) as key downstream effector; and two stress-activated
pathways, c-jun N-terminal kinase (JNK), and p38 kinase,
that respond to stress including cytokines, osmotic shock,
and irradiation. CD44 variants activate MAPK path-
ways[20], sometimes by functioning as co-receptors for
growth factors[21]. MAPK pathways, in turn, can cause
CD44 alternative splicing to include variant exons[22].
Oncogenes such as ras[7,23] and mitogens using the
MEK-ERK MAP kinase (MAPK) pathway[7], but not the
p38 pathway[24], induce CD44 promoter activity and
increase expression of certain CD44v. To test whether
these influences modulate RNA levels and alternative
splicing of CD44 in PC, we studied the CT signaling sys-




PC-3 cells (American Type Culture Collection, Manassas,
VA) were incubated in F12-K medium, 10% fetal calf
serum, and antibiotics at 37°C in a 5% CO2 incubator.
Gsα-QL cells, CT+, CT-, and CTR-cells were gifts of Dr.
Girish Shah, Univ. of Louisiana-Monroe[17]. The Gsα-QL
cells were derived from metastasizing PC-3M cells stably
transfected by a plasmid that directs expression of mutant,
constitutively active Gsα [17,19]. These three cell lines
were grown in RPMI 1640 with L-glutamine, 5% fetal calf
serum, 15% horse serum and antibiotics. Benign BPH-1
cells (from Dr. Simon Hayward, Vanderbilt Univ., Nash-
ville, TN) were grown in RPMI with 10% fetal calf serum
and antibiotics. For each experiment, cells in a flask were
trypsinized and saline washed to remove trypsin. 200,000
cells were plated per well on a 6-well plate. Cells were
adherent and 80% confluent for all experiments. Each
treatment was applied to three wells, with three other
wells as mock treated controls.
Effect of exogenous calcitonin
PC-3M cells express both CT and CT-receptor (CTR)[16].
To test the effect of solely exogenous CT on CD44, we
used the derivative, CT-minus (CT-). CT-cells have endog-
enous CT stably knocked down to undetectable levels
using anti-CT hammerhead ribozymes[25]. Salmon CT
(BAChem, Torrance, CA) was used at a physiologic 50 nM
dose[14,16], which effectively alters CD44[6], or at 250
nM. The Kd of CTR is 4–21 nM[15]. To detect acute versus
long-acting effects on RNA and protein levels, cells were
treated with 50 nM CT and harvested after 3 h or 48 h. To
determine whether CT effects on CD44 proteins resulted
from de novo protein synthesis versus protein stabiliza-
tion, cycloheximide (10 nM) was given to CT-cells after 3
hr of CT exposure, and cells harvested 1 hr, 3 hr, 6 hr, and
9 hr subsequently, similar to a prior CD44 study[26]. Also
tested were highly invasive, CT positive Gsα-QL cells[17].
Finally, to rule out non-CTR-mediated CT effects, two neg-
ative controls were tested: PC-3 cells (shown to be nega-
tive for CT receptor[14]), and cells called CTR-, derived
from PC-3M cells after anti-CT receptor ribozyme knock-
down of CTR[18]. CTR-cells have very low levels of
CD44v protein[4].
Effect of endogenous calcitonin
To test the effect of endogenous CT on CD44 RNA, we
used PC-3M cells expressing CT-pcDNA 3.1 plasmid
(CT+), which constitutively express CT[25]. 125,000 PC-
3M or CT+ cells per well were plated and allowed to grow
for 72 hours.
Inhibition of protein kinase A and MAPK components
Gsα-QL cells were chosen for these studies because they
have the highest baseline CD44v[3]. Protein kinase APage 2 of 9
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CA) was added to cells in fresh medium (1 mL/well) at 1
μM, previously shown effective in nerve cells[23] or at a
10 μM dose. Cells were incubated with H-89 for 24
hours[27] then harvested.
In similar assays, either 10 μl of 1 mM JNK inhibitor
(SP600125, Calbiochem) or 12.5 μl of 2 mM MEK inhib-
itor (PD98059, Calbiochem) in water were added, yield-
ing concentrations previously shown effective: 10 μM for
JNK[28] and 25 μM for MEK (personal communication,
Dr. Bolin Liu). p38 kinase inhibitor (SB203580, Calbio-
chem) was used at 10 μM[29,30] in DMSO, and control
cells received DMSO only. Cells were incubated for the
optimum time of 48 h[28] to show effects.
Interaction of CT with MAPK pathways
Based on results above, we tested the effect of pretreat-
ment with MEK or p38 kinase inhibitors on CT-mediated
alteration of CD44 expression. 25 μM MEK inhibitor or
10 μM p38 kinase inhibitor was added to CT-cells 4 hours
prior to administering 50 nM CT. Cells were harvested
after 48 h as above.
Real time TaqMan RNA analysis
Total RNA was prepared from cell pellets using Trizol
(Invitrogen, Carlsbad, CA) as described by the manufac-
turer. RNA was further purified by isopropanol precipita-
tion, resuspended in RNAse-free water, and its
concentration measured. Complementary DNA (cDNA)
was synthesized from 4 μg total RNA in 20 μl reaction
mixture as we did previously[9]. At least triplicate samples
were run using a primer/probe set for all CD44v that
brackets the entire variant region[6], one for CD44 total
that binds a standard exon, and 18S ribosomal RNA.
Quantitative PCR reactions were optimized to 4 μg cDNA
(0.16 μg with 18S) plus the manufacturer's master mix
and primer/probe sets (Applied Biosystems, Foster City,
CA) in a volume of 20 μl. The amplification protocol was
as follows: hold 50°C 2 min, 95°C 10 min, then 40 cycles
of (95°C for 0:15 and 60°C for 1:00) using the ABI Prism
7700 cycler (Perkin-Elmer, Waltham, MA). Primer/probe
sets for CD44v were: forward, AACGCTTCAGCCTACT-
GCAAA; reverse, TCTTCCAAGCCTTCATGTGATG; probe,
GATTTGGACAGGACAGGACCTCTTTCAATG. For CD44
total we used forward, CAACTCCATCTGTGCAGCAAA;
reverse, GTAACCTCCTGAAGTGCTGCTC; probe, CAT-
ATTGCTTCAATGCTTCAGCTCCACCTG. Primer and
probe sets for 18S were proprietary to the manufacturer.
Western blot analysis
Cultured cells were directly lysed in their wells using RIPA
buffer (Upstate Biologicals, Lake Placid, NY) with pro-
tease inhibitor Complete-mini tablet (Applied Science,
Indianapolis, IN). Protein concentration of the cell lysate
was estimated by Bradford method. Samples were
resolved on SDS-PAGE using 25 μg sample/lane with the
NuPAGE system (Invitrogen, Carlsbad, CA). 5 μl of Rain-
bow protein marker (RPN 756, Amersham, Piscataway,
NJ) was run in at least one lane. After electrophoresis for
2 hr, the protein was transferred to PVDF. Three primary
antibodies were used. To assess CD44v9 (the largest com-
ponent of the overexpressed CD44v7-10) the membrane
was reacted with neat supernatant from the hybridoma
cell line HB-258 (ATCC). CD44 standard was assessed
using anti-HCAM (DF1485, Santa Cruz Biologicals, Santa
Cruz, CA, 1:2000), which binds all CD44 isoforms. Anti-
β-actin antibody (Sigma, St. Louis) was used at a dilution
of 1:10,000. Membranes were washed 3 × 15 min in TBS
with 20 mM Tris pH 7.5 and 1:1000 dilution of goat anti-
mouse IgG antibody labeled with biotin (Bio-Rad) was
added at 1:9000 dilution in 5% skim milk for 1 hr. Reac-
tivity was detected using a chemiluminescent system
(SuperSignal West Pico Substrate, Pierce Biotechnology,
Rockford, IL). Each experimental run was conducted at
least twice.
Statistical analysis
TaqMan data were analyzed by the 2(-ΔΔCT) method [31]
to determine fold change in gene expression (mock
treated cells = 1.00). The ΔCT was taken as the difference
between the CD44v or CD44 total and the 18S ribosomal
RNA CTs. The ΔΔCT was obtained using the mean ΔCT of
mock treated cells as calibrator. Each TaqMan result was
compared to 1.00 using 2-tailed paired t-test. Statistical
significance was set at p < 0.05.
Results
Calcitonin increases CD44v
In the PC-3M-derived CT-cells, a 50 or 250 μM CT dose
after 48 h had little effect on the total amount of CD44
RNA, but the CD44v was tripled (Fig. 1a). Although differ-
ent binding affinities of primer/probe sets preclude deter-
mining CD44v as a percent of CD44 total, the relative
percent of CD44v RNA can be calculated by the 2(-ΔΔCT)
method, as increasing fivefold after 50 μM CT. The same
response, but less marked, was seen in Gsα-QL cells, at 50
and 250 μM doses. In CTR-cells and PC-3 cells – both
lacking CTR – exogenous CT had little effect. Similarly,
BPH-1 cells responded to CT with very slight stimulatory
effect on CD44v, and no effect on CD44 total. At the pro-
tein level, however, the CT-cells treated with CT showed
increases in both total and variant CD44 after just 3 h (Fig.
1b) and at 48 h (Fig. 1c). The stimulation of CD44v pro-
tein was attenuated by cycloheximide up to 9 h after CT
(data not shown). This suggests that de novo protein syn-
thesis is required and that upregulation of CD44v is not
simply a result of protein stabilization.Page 3 of 9
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while CD44 total expression was cut in half (Fig. 1d). This
suggests that endogenous CT exerts an increase on CD44
variant similar to exogenous CT.
Protein kinase A and MAP kinase pathways and their 
interaction with calcitonin
Gsα-QL cells have high basal levels of CD44v7-10; for this
reason, these cells were used to examine the effects of pro-
tein kinase A (PKA) and MAPK pathway inhibitors. PKA
inhibitor lowered CD44 total and CD44v mRNA (Fig. 2a)
and dose-dependently decreased protein for both (Fig.
2b). Downstream to PKA, inhibition of MEK significantly
decreased CD44 total (p = 0.001) and non-significantly
decreased CD44v. In contrast, inhibition of JNK had no
significant effects. p38 inhibitor led to a larger, significant
decrease in CD44 variant and a smaller significant
decrease in CD44 total (Fig. 2a). MEK and JNK inhibitors
were also tested in PC-3 cells and had no effect (data not
shown). MEK inhibitor was also tested in BPH-1 cells, in
which it reduced CD44 total and variant RNA.
To examine the dependence of CT effects on MAPK path-
ways, the CT-cells were pretreated with p38 inhibitor 4 h
prior to administration of CT. Results were similar to p38
inhibitor alone: more than 50% decrease in CD44 total
but none in CD44v (Fig. 3). This lack of CD44v suppres-
sion contrasts with p38 inhibitors marked CD44v sup-
pression in Gsα-QL cells (Fig. 2a), which have far higher
CD44v[4]. This suggests that CT mediated splicing is
through p38 kinase. In further support of this, the
expected CT induced tripling of CD44v mRNA in CT-cells
(Fig. 1a) was prevented by p38 inhibitor pretreatment.
Pretreatment with MEK inhibitor before CT also blunted
the expected rise in CD44 variant mRNA seen in Fig. 1a,
and JNK inhibitor pretreatment had no effect (data not
shown).
Discussion and conclusion
Here, we demonstrate that calcitonin (CT) causes CT
receptor-dependent increases in CD44 alternate splicing
in prostate cancer (PC), apparently mediated through p38
kinase. Furthermore, transcription but not splicing
appears to require the MEK/ERK (MAPK) pathway. Pro-
posed interactions are shown (Fig. 4).
Paracrine CT is among several growth factors that interact
with CD44[22]. In our prior in vitro studies up to 100 nM
exogenous CT[6], or CT originating endogenously (in a
PC-3 derivative called CT+ [4]), increased CD44v7-10
expression at the mRNA and protein levels. This was also
observed in LnCaP, PC-3, and PC-3M derived cells; how-
ever, we had not examined total CD44 previously. Here,
we used CT-minus (CT-) cells, an androgen-independent
PC-3M derivative, to exclude all endogenous CT influ-
ence, so any effects would be attributable solely to exoge-
nous CT. In CT-cells, the aberrant splice product is
CD44v7-10[6]. This action occurred also in Gsα-QL cells,
which are CTR+. Finally, CT+ cells showed an increase in
CD44v compared with PC-3M cells. Supporting the view
that this stimulation was CT-receptor mediated and not
nonspecific, administering CT to CT-receptor negative PC-
3 or CTR-cells did not have this effect. In further support
of this interpretation, with benign BPH-1 cells, which are
also negative for CT and CTR (personal communication,
GV Shah), exogenous CT exerted no effect.
It is a novel observation that CT increases CD44v mRNA
and protein as early as 3 h in cells that are CTR+, and has
little effect on CD44 total. A response to CT should occur
in the first several hours (personal communication, GV
Shah), and indeed these increases were evident in CD44
protein levels at 3 h and 48 h.
Since the MEK/ERK pathway and the two stress-activated
MAPK pathways are implicated in androgen-independent
prostate cancer growth[32], we tested all three for modu-
lation of CD44. We had found that CD44v7-10 protein
1a. RNA response to exogenous CT at 48 h is calcitonin (CT) receptor-dependentFigure 1
1a. RNA response to exogenous CT at 48 h is calcitonin (CT) receptor-dependent. CD44 total and variant RNA are quantified 
by triplicate TaqMan RT-PCR experiments. In benign BPH-1 cells, no response is observed to exogenous calcitonin (CT). CT-
cells, a PC-3M derivative that lack endogenous CT but have CT receptor, showed a decrease in CD44 total RNA but an 
increase in variant RNA. The Gsα-QL cell derivative showed the same trend. In CT-receptor-negative CTR- and PC-3 cells, 
there is no significant response to CT. Error bars are standard deviation. *p = 0.01; † p = 0.05 with respect to mock treated 
controls. 1b. Western blot analysis. Exogenous calcitonin given to the CT-cells for 3 h stimulates expression of CD44s at 75 
kD (top), and CD44v at 180 kD and its cleavage products below 97 kD. Comparison is shown to cells with no treatment (NT). 
β-actin analysis control confirms equal protein loading (bottom). 1c. This stimulatory effect persists at 48 h and at doses of 50 
mM or 250 mM exogenous calcitonin. Also, a time-dependent reduction in protein was observed after cycloheximide treat-
ment, suggesting that CT effect on CD44 variant requires de novo protein synthesis and does not result from protein stabiliza-
tion. 1d. CT+ cells, endogenously expressing CT, are derived from PC-3M cells and have increased RNA for CD44v (p = 0.02) 
but a decrease in CD44 total (p = 0.008).Page 5 of 9
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PC-3M[3]; and in vitro, pharmacologic stimulation of Gsα
or adenylyl cyclase raised CD44v7-10[6]. Using a PKA
inhibitor, we found reduced total and CD44v7-10 mRNA,
suggesting involvement of MEK pathway. Over half of PC
cases have activated MEK-ERK signaling, shown by immu-
nohistochemistry for p44/ERK1 and p42/ERK2[33].
To assess MAPK inhibitor effects, we chose Gsα-QL cells,
derived from metastasizing PC-3M cells that stably
express gsp mutant, constitutively active Gsα [17,19]
because they have high baseline CD44v7-10[3,6]. We
found MEK inhibitor caused similar percent decreases in
CD44 total and CD44 variant, implicating MEK in tran-
scription if not CD44v splicing. Similar effects have been
noted with ras oncoprotein, which acts on the MEK-ERK
pathway[24]. Ras activation can induce CD44 promoter
activity in fibroblasts, as shown using transient cotransfec-
tion of c-ras expression constructs and CD44 promoter
reporter gene constructs[7]. Leakiness of splice control is
proposed to lead to increased CD44v[7]. In activated T-
lymphocytes during the immune response, mutant ras
stimulation of MEK-ERK pathway increases CD44 total
mRNA and triggers inclusion of CD44v exons in the
mature RNA[24]; from our experiments, MEK seems to be
active at least in CD44 transcription in Gsα-QL cells.
Some studies have suggested a positive feedback loop cou-
pling MEK/ERK pathway and CD44v splicing. Activation
of ras oncogene in rat fibroblasts[7] and HeLa cervical
cancer[23] and of its effector, the MAP kinase pathway in
T-cells[24] both upregulate CD44v splicing. CD44 vari-
2a. RNA response to molecular inhibitors. CD44 total and variant RNA in triplicate TaqMan RT-PCR experimentsFigure 2
2a. RNA response to molecular inhibitors. CD44 total and variant RNA in triplicate TaqMan RT-PCR experiments. In subcon-
fluent Gsα-QL prostate cancer cells, significant decreases of about 50% or more were observed after protein kinase A (PKA) 
inhibitor H-89, or inhibitors of downstream signaling pathways MEK or p38 kinase, but not JNK inhibitor. Error bars are stand-
ard deviation. *p = 0.01; **p = 0.001; †p = 0.0002; ***p = 0.0001 with respect to mock treated controls. 2b. Western blot anal-
ysis. Protein kinase A inhibitor exerts a dose-dependent decrease on CD44s and CD44v compared with EtOH control in Gsα-
QL cells.Page 6 of 9
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tors that activate ras[23] or form complexes with receptor
tyrosine kinases such as c-met[8,21] to mediate cell sign-
aling. Moreover, CD44v6 promotes T-cell proliferation by
persistently activating MAP kinases[20], and CD44v8-10
causes apoptosis resistance in small cell lung cancer by
activating Rho-stimulated focal adhesion kinase
(FAK)[34].
We examined p38 kinase in benign and PC cells. In BPH-
1, CD44 total RNA decreased with p38 kinase inhibition
but variant form was unchanged. Since benign prostate
lacks the aberrant splicing leading to CD44v7-10[3], but
CD44v3-10 expression is present[35], the latter may be
the form detected in benign cells. In Gsα-QL cells, a more
marked effect on total and variant CD44 was seen. How-
ever, p38 may have CT-independent actions. Similar to
our current and previous[6] findings with CD44 and Gsα,
p38 and MEK (but not JNK) were responsive to G-protein-
coupled P2Y purinoceptor agonist ATP in PC-3 cells (CTR-
negative), and these 2 pathways were required for inva-
sion[30]. p38 has recently been recognized as a cell prolif-
eration and survival factor in PC[36] partly by regulating
IL-6 secretion[32]. Taken together with our findings about
the MEK/ERK role in CD44 transcription, this could
reflect convergence of the ERK1/2 and p38 systems in acti-
vating the MNK1 kinase, which enhances transcription of
certain targets[37], suggesting a common final pathway
that stimulates CD44 expression in PC.
We tested possible JNK pathway effects on CD44, not pre-
viously examined in the literature. JNK appears mainly
important in PC apoptosis[29,38] and promoting chemo-
therapy susceptibility. JNK inhibitor slightly decreased
CD44 total protein and did not change CD44v mRNA or
protein in Gsα-QL cells. Our data suggest that JNK is a
minor influence on CD44 expression.
Inhibition of p38 and MEK pathways affected CD44 in
Gsα-QL cells. To investigate whether either might mediate
CT's effects on CD44, we administered CT to CT-cells after
blocking either one of these pathways. CT-cells have low
baseline CD44v[6], and p38 inhibitor did not suppress
the CD44v, but it blocked the expected stimulation of
In CT-cells, the blockage of p38 kinase counteracts exogenous calcitonin (CT) stimulatory effect on CD44 variant RNA expressionFigure 3
In CT-cells, the blockage of p38 kinase counteracts exogenous calcitonin (CT) stimulatory effect on CD44 variant RNA 
expression. Triplicate TaqMan RT-PCR experiments. While p38 blockade does not affect the CT-induced decrease in CD44 
total, it does abrogate the expected tripling (Fig. 1) in CD44 variant. Conversely, MEK inhibitor moderately reduced total and 
variant CD44, and this effect was not counteracted by CT, suggesting CT does not act downstream of MEK. *p = 0.02; **p = 
0.006 with respect to mock treated controls.Page 7 of 9
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lated alternative splicing. The marked CD44v suppression
seen in Gsα-QL cells, which have endogenous CT and high
baseline CD44v, adds support for this interpretation. It is
tempting to speculate that CT signaling, raising cAMP,
may act through the effector, "exchange factor directly
activated by cAMP" (Epac, Fig. 4). Epac has been shown to
activate p38 kinase and mobilize intracellular calcium in
neurons[39]. This PKA-independent mechanism would
explain why PKA affected primarily CD44 transcription,
yet p38 showed evidence of an additional effect on splic-
ing.
To our knowledge, this is the first report in PC of how
interactions between CT, and MAP kinase pathways, dys-
regulate the expression and splicing of the CD44 mole-
cule. CD44 variant isoforms, probably through alterations
in multimerization[12] and ligand binding[4], allow
prostate cancer invasion[3,6]. This knowledge may find
application in targeting the aberrant splicing of CD44 in
PC by gene therapy, molecular inhibitor therapy, or for
sensitization to radiotherapy.
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